Walleye Capital’s Cytosorbents Corp CTSO Stock Holding History

Walleye Capital’s Portfolio CTSO Stock Details CTSO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-93,606	Closed	-$392K	–	2345
2021 Q4	$392K	Buy	+93,606	New	+$525K	0.01%	1110

Other funds holding CTSO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Avenir Corporation Alexandria, Virginia $820M AUM 2.4% 1-Year Est. Return

Skylands Capital Milwaukee, Wisconsin $763M AUM 26.49% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Walleye Capital's CTSO Position: Q1 2022 in Review

Walleye Capital sold out of Cytosorbents Corp (CTSO) in Q1 2022, closing a stake of 93,606 shares — an estimated $392K sold.

Walleye Capital first reported a position in CTSO in Q4 2021 and held it in 1 quarter. The position peaked at $392K in Q4 2021. 88 funds tracked by Wall St. Rank hold CTSO as of Q1 2022.

Walleye Capital reported no remaining Cytosorbents Corp position as of Q1 2022 after selling out during the quarter.
Walleye Capital sold 93,606 Cytosorbents Corp shares in Q1 2022, an estimated $392K.
Walleye Capital first reported a position in Cytosorbents Corp in Q4 2021 and held it in 1 quarter.
Walleye Capital's Cytosorbents Corp position peaked at $392K in Q4 2021.
88 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q1 2022.

Based on Walleye Capital's 13F filing for Q1 2022, filed 16 May 2022.